Summary Cytoplasmic phospholipase A2 (PLA2) is known to be phosphorylated and activated by MAP kinase (Lin et al 1993, Cell 72: 269-278), an important downstream component of signal transduction, whereas paclitaxel has been shown to inhibit isoprenylation of ras proteins (Danesi et al 1995 , Mol Pharmacol47: 1106-1111. Given that quinacrine (Q), a PLA2 inhibitor, and paclitaxel (P) might act at different sites in the cell signalling pathway, our aim was to test whether they were synergistic in combination against prostate cancer cells. Cell viability of PC-3, PC-3M and DU145 cells in 96 -well plates was assessed 96 h after drugs were added concurrently. Using Chou analysis, we demonstrated synergy for the combination against all three cell lines. Further, synergy was present under both conservative (mutually nonexclusive) and non-conservative (mutually exclusive) models. Studies in the nude mouse xenograft model support the finding of synergy in vitro. In DU145-bearing mice, Q (50 mg kg-') and P (0.5 mg kg-') given daily for 12 consecutive days, either concurrently or sequentially, was more effective than either drug alone, at twice the dose intensity. In an enzyme-linked immunosorbent (ELISA) apoptosis assay, arachidonic acid was able to partially reverse Q-and P-induced apoptosis, suggesting PLA2 pathway involvement. Finally, the combination of lovastatin, another inhibitor of ras isoprenylation, and quinacrine had synergistic inhibitory effects on the growth of PC-3 cells in vitro, suggesting that the combination of these two classes of compounds might serve as an attractive therapeutic approach for prostate cancer.
Despite intensive investigation, there is still no chemotherapy regimen that is reliably superior for the treatment of hormonerefractory prostate cancer (HRPC). Recently, Hudes et al (1995) showed that estramustine in combination with paclitaxel was able to reduce serum prostate-specific antigen (PSA) levels to at least 50% of baseline values in 23 evaluable patients with HRPC and concluded that the two agents might have been acting synergistically on complementary sites on the microtubule. Paclitaxel (P) stabilizes microtubules (Schiff et al, 1979; Schiff and Horwitz, 1980) , but recent evidence suggests that it can also inhibit isoprenylation of ras proteins (Danesi et al, 1995) , thereby perturbing ras signalling. We hypothesized that the responses seen in the study by Hudes et al (1995) may have been caused in part by this mechanism of action of paclitaxel. Therefore, we reasoned that paclitaxel might act synergistically with another agent that could inhibit a different portion of the ras signalling pathway.
Quinacrine (Q) is an anti-malarial agent that has been largely superseded but is still available for the treatment of giardiasis (Babb, 1995) and lupus (Wallace, 1994) . It is able to modulate drug resistance (Ford et al, 1989) and inhibit phospholipase A2 (PLA2) action. PLA2 hydrolyses the sn-2-acyl bond of membrane phospholipids to produce arachidonic acid, which has been implicated in a variety of signal transduction events, including malignant cell proliferation (Tokumoto et al, 1993; Hanada et al, 1995) . Further, histological studies suggest that membrane PLA2 expression is associated with the aggressiveness of tumour type, at least in gastric (Yamashita et al, 1994) and breast cancer (Murata et al, 1993) . The regulation of cytoplasmic PLA2 (cPLA2) is complex, but the enzyme is known to be phosphorylated and activated by MAP kinase (Lin et al, 1993) , which is itself a downstream component of ras cellular signalling.
Given that both quinacrine and paclitaxel act on different portions of the ras signalling pathway of tumour cells, we hypothesized that the quinacrine could enhance the growth-inhibitory effects of paclitaxel. Our aim was to draw together these observations from the signal transduction field and evaluate in a preclinical setting, using prostate cancer as a translational paradigm, whether these drugs in combination might be worth testing in the clinic.
METHODS Drugs
Quinacrine (ICN Chemicals, Aurora, OH, USA) was diluted with RPMI-1640 medium (Biowhittaker, Walkersville, MD, USA) into aliquots at a stock concentration of 1 mm for the in vitro experiments and stored at -20°C. Paclitaxel (Biomol, Plymouth Meeting, PA, USA) was dissolved in 100% ethanol and stored at -20°C. The lactone form of lovastatin (a gift from Merck Sharp & Dohme, Rahway, NJ, USA) was prepared as described previously (Fenton et al, 1992 ) and a 10 ,UM stock solution was stored at -20°C. For in vivo experiments, appropriate amounts of Q were dissolved in *Present address: PO Box 643, Taft, Texas, 78390, USA sterile water each week and stored at 4°C between daily treatments, while P was prepared in a cremaphor-ethanol-0.9% sodium chloride solution at a ratio of 1:1:18 (v/v/v).
In vitro dose-response experiments PC-3, PC-3M and DU145 (American Type Culture Collection, Rockville, MD, USA) were maintained in logarithmic growth phase in tissue culture flasks (Nunc Inc., Naperville, IL, USA) containing RPMI-1640 medium supplemented with 10% fetal bovine serum under standard tissue culture conditions (5% carbon dioxide, 37°C, 95% humidity). A series of 96-well plates (Falcon, Becton Dickinson, Lincoln Park, NJ, USA) were seeded with 2000 cells per well in 100 ,ul of medium and incubated overnight to allow attachment of cells. Initially, Q alone (1-20 gM) and P alone (1-100 nM) were used to establish baseline growth inhibition. In later experiments, Q was used as the background drug at a single concentration for each plate, while P concentrations were varied within the plate. In total, 25 combinations of Q (0.1, 0.5, 1, 5 and 10 gM) and P (0.5, 1, 5, 10 and 50 nM) were assessed (n = 12 wells each). Ethanol was added in appropriate amounts to equalize vehicle concentration for all wells, including controls, and was always less than 0.5%. In other experiments with PC-3, the combination of lovastatin (0.1-10 gM) with Q (0.1-10 gM) concurrently was assessed for synergistic activity as described above and below. The CellTiter 96 aqueous non-radioactive cell proliferation assay (Promega Corporation, Madison, WI, USA), a modification of the MTT assay, was used to quantify inhibition of growth.
Synergy assessed by isobologram
The inhibitory concentration (IC) at 25% (IC25), 50% (IC50) and 75% (IC75) of control values for each drug alone at 96 h was calculated by computer program (Chou and Chou, 1987) . These values were chosen because they represented the linear section of the dose-response curves for both drugs. The corresponding, experimentally derived, IC values for both drugs in combination were then plotted and compared against the line of identity for each drug alone required to produce the same inhibitory effect. Points falling below and above the line of identity are therefore defined as representing synergy and antagonism respectively.
Synergy assessed by Chou analysis
This method has been described previously (Chou et al, 1994) . Briefly, a computer program (Chou and Chou, 1987) based on the median effect principle was used to calculate combined drug effects: FaIFU = (D/Dm)m, where Fa is the fraction affected by dose D (compared with control), Fu is the fraction unaffected (=1-Fa), D is the dose, Dm is the dose required for 50% effect (i.e. IC50) and m is the coefficient of the sigmoidicity of the dose-effect curve (Chou, 1976) . Following this, the combination index (CI)-isobologram equation was used for data analysis of two-drug combinations (Chou and Talalay, 1977, 1984) , where CI < 1, CI = 1 and CI < 1 indicate synergism, additive effect and antagonism respectively.
Detection of apoptosis
This procedure has been described previously (Danesi et al, 1995) . Briefly, PC-3M cells were seeded in 100-mm Petri dishes (Falcon), incubated overnight and treated with Q and P. Controls (no drug treatment) were also prepared. At 20-22 h after drug addition, cells were harvested and lysed with hypotonic lysis buffer (10 mM Tris, 1 mM EDTA, pH 7.5) containing 0.5% (v/v) Triton X-100 for 60 min at 4°C, centrifuged and the supernatant was stored at -20°C. The supernatant, containing apoptotic DNA, was extracted, precipitated, centrifuged and recovered DNA was then washed with 70% ethanol and dried in a vacuum evaporator. After resuspension in 10 mm Tris, 1 mM EDTA, pH 7.4, and heating, DNA was subjected to electrophoresis in a 1% agarose gel containing 40 mm Tris-acetate, 1 mM EDTA, pH 8. Bands were visualized by ethidium bromide staining and photographed with a Polaroid camera after UV illumination. A 1 23-bp DNA ladder was run as a standard.
To quantitate apoptosis, we followed the manufacturer's instructions for the Cell Death Detection ELISA kit (Boehringer Mannheim, Indianapolis, IN, USA). Briefly, PC-3 cells were seeded and treated with Q and P at final concentration ratios of (Q) 2.5 gM: (P) 25 nm or (Q) 15 gM: (P) 150 nm, or Q or P alone at twice the concentrations used for the combination. In other experiments, arachidonic acid at a final concentration of 5 gM was also added to the medium. Lysed cell samples were assayed for protein concentration by the bicinchoninic acid method (BCA protein assay, Pierce, Rockford, IL, USA), corrected for protein content and loaded into wells precoated with anti-histone antibody. After the final washing step, the absorbance of the colour change induced by substrate in reaction with the peroxidase-linked 
Xenografts
For each cell line, 2 x 106 cells, together with Matrigel, were injected subcutaneously (s.c.) into each flank of each mouse in a total volume of 200 gl per injection (50% cell suspension in RPMI-1640: 50% Matrigel). Matrigel was used to improve the 'take' rate (Pretlow et al, 1991) . Tumours were monitored for growth before mice were randomized to groups on day 5 (DU 145 and PC-3M) or day 7 (PC-3). Tumour volume (TV) was calculated according to the formula TV = (length x width2)/2. This formula has previously been shown to correlate very well with excised tumour weight (PL de Souza et al, unpublished data). All animal experiments were carried out with the approval of the Animal Ethics Committee of the University of Virginia and monitored according to established guidelines.
Design of in vivo experiments
Three separate experiments were carried out in athymic mice (Harlan Sprague Dawley, Indianapolis, IN, USA), one for each cell line: DUI45, PC-3 and PC-3M. In the first experiment, 39 male mice bearing DU 145 xenografts were randomized into five groups, comprising control (C, sterile water daily), quinacrine alone (Q, 100 mg kg-' daily), paclitaxel alone (P, 1 mg kg-' daily), quinacrine and paclitaxel given concurrently (QP concurrent, Q 50 mg kg-' + P 0.5 mg kg-' daily) and quinacrine and paclitaxel given sequentially (QP sequential, Q 100 mg kg-' on day 1, then P 1 mg kg-' on day 2, alternated daily). Sterile water or Q was given by oral gavage through animal feeding needles (Popper & Sons, New Hyde Park, NY, USA), whereas P was given by bolus The parameters Dm, m and rare the antilog of the abscissa, slope and the linear correlation of the median effect plot, which indicate the potency of the drug (IC50), the shape of the concentration-effect curve and the conformity of the data to the mass-action law respectively (Chou et al, 1994) . The number of estimations of the effect of each concentration combination is indicated by n. Values are means ± standard errors.
intravenous injection. All volumes delivered were 200 ,ul, regardless of route, and mice were treated for 12 consecutive days. Actual drug dosages for each group were calculated according to the most recent average weight available for each group, obtained twice weekly. In the second experiment, 36 PC-3-bearing mice were randomized in to four groups: C, Q, P or QP concurrently. Q was given on a daily x 5 schedule, with 2 days off, for a total 14 days, and P was given only once a week. In a similar design, 40 PC-3M-bearing mice were given P daily for 5 days, with 2 days off, for 14 days, while the Q schedule remained the same.
Derivation of drug doses used for in vivo experiments
Q doses were determined from previous experiments. P doses were chosen to provide blood levels of approximately 1 gmU to simulate concentrations typically achievable by 24-h infusion (Jamis-Dow et al, 1993) and were based on earlier work on the pharmacokinetics of paclitaxel in nude mice (Eiseman et al, 1994) . Doses were halved for each drug in the QP groups in the hope that if the combination proved to be as or more effective than either agent alone at double the dose, we could conclude that the combination showed at least additive activity. This reasoning was based on the CI-isobologram equation derived by Chou and Talalay (1984) :
where (Dalone) is the dose of drug 1 alone required for a given effect (fa), (D omb) ,is the dose of drug 1 in the combination required for a given effect (fa), (Da,one) 2 is the dose of drug 2 alone required for a given effect (f ), (Dcom )2 is the dose of drug 2 in the combination required for a given effect (f), CI is the combination index, a measure of the degree of synergy, and ax = 0 if the effects of the two drugs are mutually exclusive (Chou, 1991; Chou and Chou, 1987 (Heitjan et al, 1993) . When multiple groups were compared, a one-way ANOVA was used to establish a significant difference among groups first, before comparing specific pairs. In the case of nonnormally distributed groups, non-parametric methods were used to examine statistical significance. Unless otherwise specified, other statistical comparisons were also made by ANOVA. SigmaStat for Windows (Jandel Scientific, San Rafael, CA, USA) was used for statistical calculations.
RESULTS

In vitro dose-response experiments
A concentration-and time-dependent effect on cell viability exists for both Q and P alone against all three hormone-refractory prostate cancer cell lines tested (data not shown). At 96 h, the IC 50 s for Q alone were 3.1, 4.7 and 3.5 gm for PC-3, PC-3M and DU 145 respectively, whereas the coffesponding IC 50 s for P were 21, 17 and 10 nm respectively (Table 1) . Figure I (A-C) demonstrates the synergistic activity of nonconstant dose ratios of Q and P for PC-3, PC3M and DUI45 respectively. In general, the curves for IC 25' IC 50 and IC 75 all show the same concave appearance, relative to the line of identity for each IC value. Only the IC 75 line of identity is shown in Figure I for illustration. Overall, these results indicate synergism for the combination of Q and P at non-constant ratios for the three cell lines. Synergy assessed by Chou analysis By Chou analysis, most combination dose ratios of Q and P produced marked synergy, under both mutually exclusive and mutually non-exclusive conditions (data not shown), although apparent antagonism also occurred. Increasing doses of both drugs, in general, produces more growth inhibition (higher F a), but synergy becomes more apparent at higher Q doses (5-10 gM), where the combination index was less than one for all dose combinations tested. Figure 2 plots the combination index (CI) values for a variety of Q/P ratios, grouped by varying background Q levels. In general, the higher Q levels (5 and 10 gM) are associated with more consistent synergism across the range of P levels tested, although synergism is seen with Q concentrations as low as 0.1 JIM. At the lower Q doses (0.1, 0.5 and 1 gM), lower P doses are associated with antagonism. Taken together, these results suggest that a minimum threshold Q concentration of between 0.1 and 0.5 gM is required for synergy, and at this range P concentrations between 5 and 50 nm appear to be associated with the most synergy.
Synergy analysis by isobologram methods
Effect of sequence of drug administration on cell viability Figure 3 depicts the effect on cell viability of changing the sequence of drug administration from 24 h Q followed by 24 h P, and the reverse. At 48 h, there is no effect of the sequence of administration of drugs on cell viability for PC-3M or DU145. The degree of growth inhibition of PC-3 cells increases when P is given before Q.
Synergy of quinacrine-and paclitaxel-induced apoptosis Figure 4 demonstrates apoptosis of PC-3M cells induced by 30 gM Q alone, 100 nM P alone and the combination of 10 gM Q with 10 nM P. Despite a markedly reduced dose of both drugs in combination, DNA fragmentation is still visible, indicating that the combination may be synergistic in inducing apoptosis. This observation was confinned by an ELISA method, in which 2.5 ,UM Q combined with 25 nM P produced as much apoptosis as 5 ,UM Q alone and more apoptosis than 50 nM P alone (data not shown). In other experiments, the addition of 5 ,UM arachidonic acid was associated with a 37% reduction in apoptosis induced by the combination (data not shown), suggesting that the combination of Q and P does indeed perturb elements of the PLA2 signal transduction pathway, the effects of which are partially reversed by the addition of exogenous arachidonic acid.
Effect of lovastatin and quinacrine on PC-3 To confirm the hypothesis that quinacrine can enhance the action Time (days) of inhibitors of ras protein function, we also used lovastatin, a competitive inhibitor of HMGCoA reductase and an inhibitor of Figure 5 The effect of quinacrine and paclitaxel on the growth of DU145 ras signalling (Hohl and Lewis, 1995) , concurrently with Q against xenografts in nude mice. Treatment groups (and their respective doses) are:
PC-3 cells, and assessed the combination for synergy with Chou controls (0, sterile water); quinacrine alone (E, 100 mg kg-'), paclitaxel alone analysis. In general, the results suggest that this combination also (A, 1 mg kg-'), quinacrine (50 mg kg-') + paclitaxel (0.5 mg kg-') concurrently (v) and quinacrine (100 mg kg-') + paclitaxel (1 mg kg-') has synergistic effects (data not shown). For lovastatin concentrasequentially on alternate days (*). Time (days) is plotted along the abscissa, tions of 1 ,UM, all concentrations of Q (0.1-1O gM) were synergistic and tumour size (mm3) along the ordinate. Treatment began after mice were in inhibiting growth of PC-3 cells, while for lovastatin concentrarandomized to assigned groups 5 days after cells were implanted subcutaneously in both flanks. Error bars indicate the s.e.m. (n = 7-9 mice tions lower or higher than 1 ,UM, some ratios suggested mild for each group). The arrow represents the start of treatment synergy and others suggested mild antagonism (data not shown).
British Journal of Cancer (1997) 75(11), 1593-1600 0 Cancer Research Campaign 1997 Table 2 Combination effects of quinacrine (Q) and paclitaxel (P) in various non-constant concentration ratios against PC-3, PC-3M and DU145 Q (gm) P (nM) Activity of paclitaxel and quinacrine against xenografts Using RMANOVA, a statistically significant difference (P < 0.05, q = 5.06, Student-Newman-Keul's method) was found between the QP combination and the P alone group, suggesting that the combination was truly synergistic in vivo ( Figure 5 ). In PC-3 and PC-3M xenografted mice, no differences between any of the treatment arms were seen (data not shown).
Toxicity of paclitaxel and quinacrine Other than a yellow pigmentation associated with Q treatment, noticeable after about 3 days, no obvious toxicity resulted from the combination of Q and P. For each group, the mean weight loss was less than 5% over the entire treatment period.
DISCUSSION
We have shown that quinacrine and paclitaxel appear to act synergistically in inhibiting the in vitro growth of three hormoneindependent human prostate cancer cell lines, PC-3, PC-3M and DU145. Our initial observations suggested that this synergy was most consistent at higher quinacrine concentrations (5-10 gM), raising the possibility that a threshold concentration of quinacrine is required for full expression of synergy. As PLA2 has a role in many signal transduction pathways, we speculate that exceeding such a threshold may be required for suppression of its functions.
Synergy was seen at quinacrine concentrations as low as 0.1 gM, indicating that the exact combination ratio of these drugs may not be an important determinant of their synergistic activity. Synergy was also seen in DU145-bearing mice, where the combination inhibited the growth of DU145 tumour size more effectively than either quinacrine or paclitaxel alone (Figure 5 ), the differences being statistically significant by RMANOVA (Heitjan et al, 1993 (Chou, 1991; Chou and Chou, 1987) , if drug doses in combination are 50% of doses of each drug alone, provided the effect of the combination is equal to or better than for each drug alone (see Methods). In the apoptosis experiments, although the degree of apoptosis induced by the combination looked qualitatively less than for either quinacrine or paclitaxel alone (Figure 4) , much less than 50% of the dose of each agent was used.
Quantitating the apoptosis by spectophotometric means would not have been helpful, because both the drug doses and, as it happened, the degree of apoptosis, were different. By the ELISA British Joumal of Cancer (1997) 75(11), 1593-1600 method, however, we were able to show quantitatively that there was at least additive activity for the combination in inducing apoptosis. The finding that arachidonic acid can partially reverse the apoptosis induced by the combination of quinacrine and paclitaxel suggests involvement of the PLA2 pathway. However, it would be simplistic to suggest that this was also evidence for the mechanism of synergy between quinacrine and paclitaxel, because both drugs have other documented actions. Further, ras also has other functions than progressing to PLA2 activation (see Khosravi-Far and Der, 1994 for review), and PLA, itself is activated by other pathways (see Chang et al, 1987 for review) . Nevertheless, the observation that lovastatin, another inhibitor of ras isoprenylation and function (Hohl and Lewis, 1995; Ruch et al, 1993) , has synergistic activity in combination with quinacrine suggests that the rasIPLA, pathway might be a fruitful target for anti-cancer therapy.
Quinacrine enhances the action of paclitaxel, but the exact mechanism of action is unclear and may result from reasons other than its effect on the ras signalling pathway. Ford et al (1989) showed that quinacrine was able to reverse some of the effects of the mdr phenotype in doxorubicin-resistant MCF-7/DOX cells. However, mdrl mRNA levels in primary prostate cancer, while common, are expressed at low levels as determined by RNApolymerase chain reaction (PCR) (Siegsmund et al, 1994) . Consequently, reversal of mdr phenotype effects by quinacrine may not play a major role in our results. Others (Zidovetzki et al, 1990) have found that quinacrine can alter membrane phospholipid function. This may be advantageous in that the non-specific nature of the disruption could also theoretically cause perturbation of ras, as well as PLA,, function, both of which require relocation to the plasma membrane in order to be activated.
The prevalence of ras mutations in prostate cancer is of the order of 4% in American men and 25% in Japanese men (Isaacs et al, 1994) . However, as these estimates were based on a spectrum of disease, from latent carcinoma to metastatic disease, the true incidence in HRPC is unknown. Because ras has been implicated in the progression to hormone-resistant disease (Voeller et al, 1991) , and transfection of dominant-negative H-ras mutants into PC-3 cells has been shown to be very effective in inhibiting growth (Ogiso et al, 1994) , further investigation on the role of ras in the development and growth of metastatic prostate cancer is warranted.
While a number of ras pathway inhibitors are presently in early clinical trials, a certain amount of clinical experience with paclitaxel and quinacrine already exists, and it seems reasonable to use these drugs for initial clinical trials to test the concept of combining ras/PLA, pathway inhibitors. The most clinically useful steady-state concentrations of quinacrine and paclitaxel associated with synergy may be around 0.5 ,uM and 5-10 nm respectively. As short infusions of paclitaxel at typical clinical doses (> 100 mg m-2) are associated with much higher concentrations (Jamis-Dow et al, 1993) than represented by our in vitro studies, the conditions for synergy appear easily achievable. Further, because synergy was seen over a range of drug concentration ratios, faithful duplication of the in vitro conditions for synergy may not be required. Peak plasma concentrations of up to
